NEW YORK (
CHANGE IN RATINGS
(ADSK - Get Report) downgraded at Jefferies to Hold from Buy, Jefferies said. $34 price target. Weaker data and limited uplift from suites. Hold rating.
(ADTN) upgraded at Mizuho to Buy, Mizuho said. $22 price target. Business will likely bottom out in the fourth quarter.
(CMI - Get Report) upgraded at BMO from Market Perform to Outperform, BMO Capital said. $120 price target. Global growth appears to be stabilizing.
downgraded at Piper from Neutral to Underweight, Piper Jaffray said. Valuation call, based on a $49 price target.
(DVN - Get Report)
downgraded at UBS to Neutral from Buy, UBS said. $60 price target. Long term outlook dims.
Devon Energy downgraded at Citigroup. DVN was downgraded to Neutral from Buy, Citigroup said. $62 price target. Lower costs, but reining in production growth outlook.
upgraded at UBS to Neutral from Sell, UBS said. $30 price target. Shares now reflect a lower dvidend.
upgraded at Baird from Underperform to Neutral, Robert Baird said. Valuation call, based on a $13 price target.
upgraded at BMO from Underperform to Market Perform, BMO Capital said. $23 price target. Near-term visibility is improving.
(JNPR - Get Report)
upgraded at Cantor from Hold to Buy, Cantor Fitzgerald said. $21 price target. Company is cutting costs and is leveraged to higher carrier spending.
upgraded at UBS to Buy from Neutral, UBS said. $38 price target. Improved relative growth rate supports raised valuation.
downgraded at Wedbush from Outperform to Neutral, Wedbush said. $20 price target. Estimates also cut, as the company has reduced visibility.
upgraded at BMO to Outperform, BMO Capital said. Valuation call, based on a $94 price target.
downgraded at Caris from Buy to Above Average, Caris & Co. said. $129 price target. Company is seeing slower demand for consumer healthcare and nutritionals.
PSS World Medical
downgraded at UBS to Neutral from Buy, UBS said. $29 price target. 10Q reveals inline results.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts